Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03361124

Oxytocin Dosing at Planned Cesarean Section and Anemia

Oxytocin Dosing at Planned Cesarean Section and Postpartum Anemia: A Comparison of Two Protocols

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Milton S. Hershey Medical Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

Patient's with planned cesarean sections will be randomized to receive either standard 20 mU in 1L as a bolus following delivery of the placenta or 20 mu in 1L following delivery of the placenta plus an additional 20 mU in 1L over 8 hours.

Detailed description

The purpose of this study is to examine the impact of differential dose protocols commonly utilized in the post cesarean period to determine if laboratory definitions of anemia are different. Oxytocin is an antidiuretic hormone that is utilized after delivery of the fetus and placenta to contract the uterus and decrease blood loss both at the time of surgery and in the post-partum period. Here at the Penn State Hershey Medical center the investigators will use 20 units of oxytocin in a 1 L bag of LR in bolus fashion after delivery of the placenta. Other protocols use an extended course of therapy using 20 units of oxytocin in a 1 L bag of LR in a bolus plus an additional 20 units of oxytocin in a 1 L bag of LR over an 8 hour period of time. We hypothesize that: * Women who receive the standard 20 mU of oxytocin in 1L of LR in bolus fashion plus 20 mU in 1L over 8 hours will have a decreased reduction in pre-operative vs post-operative hematocrit and hemoglobin versus those that receive 20 mU in 1L of LR. * Women who receive the standard 20 mU of oxytocin in 1L of LR in bolus fashion plus 20 mU in 1L over 8 hours will have decreased blood loss by weight in the postpartum period compared to patients who receive 20 mU in 1L of LR.

Conditions

Interventions

TypeNameDescription
DRUGOxytocinAdministration of additional 20 mU Oxytocin

Timeline

Start date
2019-03-01
Primary completion
2020-03-01
Completion
2020-03-01
First posted
2017-12-04
Last updated
2019-02-21

Source: ClinicalTrials.gov record NCT03361124. Inclusion in this directory is not an endorsement.